Avobenzone
Anthelios, Capital Soleil, Shade Uvaguard (avobenzone) is a small molecule pharmaceutical. Avobenzone was first approved as Shade uvaguard on 1992-12-07. It is used to treat photosensitivity disorders in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil (discontinued: Shade uvaguard)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Octinoxate
+
Oxybenzone
Avobenzone
+
Ecamsule
+
Octocrylene
+
Titanium dioxide
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| al0038100 alba hw sunscreen coconut milk spf50 | OTC monograph final | 2021-02-05 |
| al0038100 alba ve sunscreen fragrance free spf50 | OTC monograph final | 2021-02-05 |
| al0038200 alba ve sunscreen kids spf50 | OTC monograph final | 2021-02-05 |
| al0082706 alba botanica hw sunscreen green tea spf45 | OTC monograph not final | 2021-04-12 |
| alba botanica natural very emollient sunscreen kids spf40 | OTC monograph final | 2012-05-03 |
| alba botanica natural very emollient sunscreen spf40 | OTC monograph final | 2012-04-30 |
| alba botanica natural very emollient sunscreen sport spray spf40 | OTC monograph final | 2012-05-08 |
| alba even advanced sea moss moisturizer spf15 | OTC monograph not final | 2022-12-02 |
| alba hawaiian sunscreen green tea spf45 | OTC monograph not final | 2014-11-14 |
| alba ve sunscreen spf30 fragrance free | OTC monograph not final | 2014-11-14 |
Show 15 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| photosensitivity disorders | HP_0000992 | D010787 | L57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanosis | D008548 | HP_0001480 | L81.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sun protection factor | D059405 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Avobenzone |
| INN | avobenzone |
| Description | Avobenzone is a member of dihydrochalcones. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 70356-09-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200522 |
| ChEBI ID | — |
| PubChem CID | 51040 |
| DrugBank | — |
| UNII ID | G63QQF2NOX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 582 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
144,440 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use